Skip to content

Inspection Record

GenTrac, Inc. — FDA 483 Findings

US FDAInspected 2025-07-30Published 2026-10-27 4 findingsCleaning validationEquipment and facilityQuality unit oversightLaboratory and QC controls

Inspectors Lizaida Perez · Peng ZhouThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Cleaning validation

Microbiological recovery studies used to validate the swab testing method used in cleaning validation are inadequate.

2Equipment and facility

(b) (4) identified on equipment product contact surfaces is not characterized nor its potential impact to drug substance quality assessed.

3Quality unit oversight

Procedures regarding segregation of duties are inadequately defined or not always followed in the Quality Unit.

4Laboratory and QC controls

Training and qualification related to laboratory operations are not adequately documented or implemented and associated corrective actions are not demonstrated to be effective.

A record as of the US FDA document published on 2026-10-27. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

GenTrac, Inc. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.